Brainstorm Cell Therapeutics Inc (OQ:BCLI)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 1325 Avenue Of Americas, 28Th Floor
NEW YORK NY 10019
Tel: N/A
Website: https://brainstorm-cell.com
IR: See website
<
Key People
Jacob A. Frenkel
Independent Chairman of the Board
Chaim Lebovits
President, Chief Executive Officer
Stacy R. Lindborg
Co-Chief Executive Officer
Alla Patlis
Chief Financial Officer, Controller
Uri Yablonka
Executive Vice President, Chief Business Officer, Secretary, Director
Ibrahim B. Dagher
Executive Vice President, Chief Medical Officer
Business Overview
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Financial Overview
For the fiscal year ended 31 December 2023, Brainstorm Cell Therapeutics Inc revenues was not reported. Net loss decreased 29% to $17.2M. Lower net loss reflects Research and development - Balancing val decrease of 29% to $9.6M (expense), Stock-based Compensation in SGA decrease of 74% to $320K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.66 to -$0.40.
Employees: 29 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $33.85M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$21.17M as of Dec 31, 2023
Net annual income (TTM): -$17.19M as of Dec 31, 2023
Free cash flow (TTM): -$20.48M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 68,341,857 as of Mar 27, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.